FindTrial
Sign In

vasanjana and shadanga ghrita guggulu in shushkakshipaka(meibomian gland dysfunction)

evaluation of vasanjana and shadanga ghrita guggulu in shushkakshipaka(meibomian gland dysfunction)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034351
Enrollment
40
Registered
2021-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H028- Other specified disorders of eyelid Health Condition 2: H018- Other specified inflammations of eyelid

Interventions

Intervention1: vasanjana in shushkakshipaka: local application of of vasanjana over the eye lid 60mg twice a day at the interval of 12 hours for 45 days. Control Intervention1: shadanga ghrita guggulu

Sponsors

Gurukul campus UAU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patient presenting with signs and symptoms of Shushkakshipaka and Meibomian Gland Dysfunction. Best corrected Visual acuity- 6/9 and above & N6 both eyes. Patient fit for Anjana karma and Ghrit pana.

Exclusion criteria

Exclusion criteria: Patient having best corrected visual acuity Patient suffering from Aqueous deficiency dry eye and other causes of EDE (evaporative dry eye). Patient having infective anterior segment disorders Patients suffering from specific eye lid disorders like ectropion, entropion, anterior blephritis ,tumors, skin allergies (acne rosacae), lagophthalmous and having previous Lid Surgeries. Patient with Systemic disorders eg.DM, HTN, RA, Heart disease and hyperlipidemia. Patient who are unfit for Anjana karma and Ghritapana.

Design outcomes

Primary

MeasureTime frame
relief in subjective parameters like- dryness(rukshata) Foreign Body Sensation (Gharsha) Transient Blurring of vision (Aviladarshanam) Itching Sensation(kandu) Timepoint: at 1st day ,15th day,30th day and 45 day.—

Secondary

MeasureTime frame
relief in objective parameters- abnormal lid margin finding of vascularity plugging of gland orifices lid margin irregularity lid margin thickening partial gland gland dropout ocular protection index TBUT test fluorescein staining rose bengal staining Timepoint: at 1st day,15th day,30th day and 45th day of the trial—

Countries

India

Contacts

Public ContactdrAditi

Gurukul campus UAU

docaditi24@gmail.com9719353123

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026